NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report were sliding on heavy trading volume late Friday afternoon as the company prepares to post 2016 third quarter results after Tuesday's market close.

Analysts surveyed by FactSet are looking for the Foster City, CA-based biopharmaceutical company to report earnings of $3.08 per share on revenue of $7.45 billion for the quarter.

In the year-ago period, Gilead posted earnings of $3.22 per share on revenue of $8.30 billion.

BMO Capital Markets said recently that investors who are "looking for a better entry point" into the stock "may wait for 2016 third quarter earnings."

The firm noted that Gilead shares could remain volatile following its report, due to slowing hepatitis C drug sales.

"Exiting the third quarter, we expect investor focus to shift to 15 pipeline data readouts, which range across a variety of products and diseases," BMO added.

TST Recommends

The firm has a "hold" rating and $98 price target on Gilead shares.

More than 10.52 million shares have traded hands so far today vs. the 30-day average of 9.28 million shares.

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings rated this stock as a "buy" with a ratings score of B.

The company's strengths can be seen in multiple areas, such as its notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

You can view the full analysis from the report here: GILD

Image placeholder title